Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy may simplify steroid diabetes care

NCT ID NCT07117240

Disease control Sponsor: Medical University of Warsaw Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a combination of a GLP-1 drug (lixisenatide) plus long-acting insulin works better than standard intensive insulin therapy for people whose diabetes is caused by steroid medications. About 100 adults with conditions like asthma or arthritis who need long-term steroids will be enrolled. The goal is to see if the combo approach improves blood sugar control and reduces the need for extra insulin shots.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lixisenatide plus insulin glargine
What this could lead to
If this works, it could offer a simpler, more effective way to manage steroid-induced diabetes with fewer injections and better blood sugar control.
What could go wrong
This is a small, early-phase trial with only 100 participants, so results may not apply to everyone. The combination therapy may not prove superior or could cause side effects like nausea or low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years of age) * Patients with type 2 diabetes and SIH, or diagnosed with SID requiring insulin * Patients undergoing long-term oral GC therapy for the following indications: * Nephrotic syndrome * Asthma * Rheumatoid arthritis * Psoriatic arthritis * Polymyalgia rheumatica * Synovitis associated with osteoarthritis * Sarcoidosis * Tubulointerstitial nephritis * Atopic dermatitis * Pemphigus * Informed consent Exclusion Criteria: * \- Age \<18 years * Type 1 diabetes * Critically ill patients in a life-threatening condition requiring intensive care and medical support to sustain vital functions, as defined by an Allgöwer index \>1.0 * eGFR \<30 mL/min * History of acute pancreatitis or gallstone disease * Lack of consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus hyperglycemia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes Steroid induced hyperglycemia Steroid-induced diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Warsaw Medical University

    Warsaw, Warsaw, 02-097, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.